Best-in-Class Specialty Services, Strategy & Technology

Explore our end-to-end solutions that close the gap between providers, patients and drug manufacturers to promote better adherence rates, better care, and better outcomes.

Pipeline Management & Strategy

We offer an innovative, patient-centered way to build your health system strategy with efficiency, integrity and rigor. We proactively research and identify new drugs— often 18–24 months before FDA approval — to prioritize market opportunities and identify unmet needs prior to launch. Drug manufacturers receive real-time product launch feedback from the people treating patients, creating opportunities for course correction early in treatment.

Network Strategy & TelemetryRx® Data Aggregation

We help design single source network level contracting agreements for limited distribution drugs (LDDs), connecting you and your products to our national network of health systems. Shields’ proprietary therapy management system, TelemetryRx® delivers industry-aggregated, real-world data from a single, standardized source.

Account Management

account management relationships image

Our drug manufacturer relationships are strategic, long-term and collaborative business partnerships. We provide a single point of contact for data contracting, eliminating the need to negotiate and manage multiple contracts with health systems while expanding access to more patients. Our experts can support your product strategy in everything from contract management and implementation to LDD pathway support and research.

Rare Disease & Complex Therapy Support

Patients are at the center of the Shields Care Continuum, and that’s why our dedicated teams offer hands-on clinical management for rare and complex diseases. Because there is no handbook for rare diseases, our offering spans services like specialty drug-specific programs and designs; ETASU REMS program management and audit readiness; medical billing program solutions, and much more. Our experience includes rare conditions such as hereditary angioedema (HAE), myasthenia gravis (MG), hemophilia, and pulmonary arterial hypertension (PAH).

Rare Disease & Complex Therapy Support image

Redefining the Role of Health Systems as a Specialty Pharmacy Solution for Drug Manufacturers

This white paper discusses how a specialty pharmacy acceleration company allows drug manufacturers to access the expertise of health systems and their specialty pharmacies through a single point of contact. This in turn allows health systems to provide high-quality, continuous care that can ultimately result in better health outcomes.

The Shields Performance Platform for Drug Manufacturers makes it easy for manufacturers to work with health systems by:

  • Aggregating data
  • Requiring and supporting high performance standards
  • Providing analytics and insights on real-world drug usage
  • Ensuring patients initiate and stay on therapy
Name(Required)
This field is for validation purposes and should be left unchanged.

Hear From Our Partners

Developing our data capabilities to gain access to limited-distribution networks has allowed us to serve our community more effectively, capture revenue that was previously lost, and strengthen our specialty pharmacy.

VICE PRESIDENT, PHARMACY

MONUMENT HEALTH

(an Excelera member)

Speech Bubble Icon

COLLABORATE WITH US.

Complete all fields, and one of our Trade Team members will email you.

"(Required)" indicates required fields

Name(Required)
This field is for validation purposes and should be left unchanged.